COVID-19 and Diabetes Mellitus: The Impact of Two Pandemics
Keywords:COVID-19, Diabetes Mellitus, Hypoglycemic Agents, SARS-CoV-2
Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41:bnaa011. DOI: https://doi.org/10.1210/endrev/bnaa011
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782–92. DOI: https://doi.org/10.1016/S2213-8587(20)30238-2
Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, et al. Cytokine storm in COVID-19: immunopathogenesis and therapy. Medicina. 2022;58:144. DOI: https://doi.org/10.3390/medicina58020144
Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43:867-9. DOI: https://doi.org/10.1007/s40618-020-01236-2
Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500-15. DOI: https://doi.org/10.1007/s00125-020-05180-x
Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, et al. Guidance on the management of diabetic ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabet Med. 2020;37:1214-6. DOI: https://doi.org/10.1111/dme.14328
Hasan SS, Kow CS, Bain A, Kavanagh S, Merchant HA, Hadi MA. Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients. Expert Opin Pharmacother. 2021;22:229-40. DOI: https://doi.org/10.1080/14656566.2020.1837114
Pranata R, Henrina J, Raffaello WM, Lawrensia S, Huang I. Diabetes and COVID-19: the past, the present, and the future. Metabolism. 2021;121:154814. DOI: https://doi.org/10.1016/j.metabol.2021.154814
How to Cite
Copyright (c) 2022 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.